Active, not recruitingPHASE1, PHASE2NCT05025956

Senolytic Agent Improve the Benefit of Platelet-Rich Plasma and Losartan

Studying Rapidly involuting congenital hemangioma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Steadman Philippon Research Institute
Principal Investigator
Johnny L Huard, PhD
Steadman Philippon Research Institute
Intervention
Fisetin(drug)
Enrollment
68 target
Eligibility
18-80 years · All sexes
Timeline
20212024

Study locations (1)

Collaborators

United States Department of Defense

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05025956 on ClinicalTrials.gov

Other trials for Rapidly involuting congenital hemangioma

Additional recruiting or active studies for the same condition.

See all trials for Rapidly involuting congenital hemangioma

← Back to all trials